2. Search Result
Search Result
Results for "

Analgesic effect

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

15

Peptides

7

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108449
    Acoltremon
    1 Publications Verification

    WS-12; AR-15512; AVX-012

    		 TRP Channel Cancer
    Acoltremon (WS-12; AR-15512) is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .
    Acoltremon
  • HY-105808
    Furobufen

    		Others Neurological Disease Inflammation/Immunology
    Furobufen, an anti-inflammatory agent, produces antiarthritic, antipyretic effects. Furobufen has an analgesic effect in inflamed tissue .
    Furobufen
  • HY-P3445
    Anrikefon

    HSK21542

    		 Opioid Receptor Neurological Disease
    Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effect .
    Anrikefon
  • HY-P3445A
    Anrikefon acetate

    HSK21542 acetate

    		 Opioid Receptor Neurological Disease
    Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect .
    Anrikefon acetate
  • HY-103344
    ZJ43

    		Aminopeptidase mGluR Neurological Disease Inflammation/Immunology
    ZJ43 is a potent NAAG peptidase inhibitor, with an IC50 of 2.4 nM and a Ki of 0.8 nM. ZJ43 sufficiently activates group II mGluR and reduces some of the behavioral effects of PCP. ZJ43 shows an analgesic effect in neuropathic and inflammatory and pain models .
    ZJ43
  • HY-147907
    Adenosine receptor inhibitor 1

    		Adenosine Receptor Neurological Disease Inflammation/Immunology Cancer
    Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with Ki values of >1000, 68.5, >1000, >1000 nM for A1AR, A2AAR, A2BAR, A3AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases .
    Adenosine receptor inhibitor 1
  • HY-149269
    COX-2-IN-30

    		COX Carbonic Anhydrase LOX-1 Inflammation/Immunology
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect .
    COX-2-IN-30
  • HY-145236
    Analgesic agent-1

    		Others Others
    Analgesic agent-1, a potent analgesic agent, shows significant analgesic effect.
    Analgesic agent-1
  • HY-U00081
    Pyrrolifene

    		Others Neurological Disease Inflammation/Immunology
    Pyrrolifene is an analgesic with anti-inflammatory effect.
    Pyrrolifene
  • HY-149274
    Sigma-1 receptor antagonist 4

    		Sigma Receptor Neurological Disease
    Sigma-1 receptor antagonist 4 (Compound 32) is a potent σ1R antagonist that significantly enhances the analgesic effect of morphine and rescues morphine-induced analgesic tolerance, with potential to prevent morphine tolerance .
    Sigma-1 receptor antagonist 4
  • HY-129668
    Bremazocine

    		Adrenergic Receptor Neurological Disease
    Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .
    Bremazocine
  • HY-136720
    ZXX2-77

    		Others Others
    ZXX2-77 is a cyclooxygenase-1 (COX-1) selective inhibitor belonging to the benzenesulfonylanilide class of compounds. It is reported as a novel analgesic that does not cause gastric damage. ZXX2-77 has a weak analgesic effect but exhibits potent COX-1 inhibitory activity in vitro. The low oral absorption rate of ZXX2-77 leads to its weak analgesic effect in vivo. At a dose of 30 mg/kg, the maximum plasma concentration of ZXX2-77 (1.2 mM) did not reach its COX-1 IC50 value (3.2 mM). In contrast, its derivative ZXX2-79, although weaker in vitro COX inhibitory activity, is better absorbed, exhibits stronger analgesic effect and hardly causes gastric damage. These findings suggest that ZXX2-77 and its derivatives as COX-1 selective inhibitors may become effective analgesics that do not cause gastric damage.
    ZXX2-77
  • HY-N0398
    Sec-O-Glucosylhamaudol

    		Opioid Receptor Neurological Disease
    Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .
    Sec-O-Glucosylhamaudol
  • HY-118756
    Anirolac

    RS37326

    		 Endogenous Metabolite Inflammation/Immunology
    Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .
    Anirolac
  • HY-122323
    L-Leucyl-L-arginine

    Leucylarginine

    		 Others Others
    L-Leucyl-L-arginine (Leucylarginine) is a compound that inhibits the analgesic effect of systemically administered L-arginine in a carrageenan-induced hyperalgesia model in mice when administered intracerebroventricularly.
    L-Leucyl-L-arginine
  • HY-111025
    Ectylurea

    		Others Neurological Disease
    Ectylurea，a N-acylurea，can be used in studies of tension and anxiety symptoms, has no effect on the autonomic nervous system, and has no convulsive, analgesic or antispasmodic activity in animals .
    Ectylurea
  • HY-149498
    Carbonic anhydrase inhibitor 15

    		Carbonic Anhydrase Neurological Disease Inflammation/Immunology
    Carbonic anhydrase inhibitor 15 (Compound 8) is a carbonic anhydrase inhibitor (Ki: 8.5 nM for hCA II). Carbonic anhydrase inhibitor 15 has analgesic effect .
    Carbonic anhydrase inhibitor 15
  • HY-W709349
    Flupirtine hydrochloride

    D 9998 hydrochloride

    		 Potassium Channel iGluR Inflammation/Immunology
    Flupirtine hydrochloride (D 9998 hydrochloride) is a selective neuropotassium channel opener with analgesic activity. Flupirtine hydrochloride is used to inhibit a variety of pain conditions, including chronic musculoskeletal pain, migraines, and neuralgia. Flupirtine hydrochloride has antidepressant and antioxidant properties and may increase the analgesic effect in combination therapy with morphine. Flupirtine hydrochloride relieves abnormally increased muscle tension and has a muscle relaxant effect. Flupirtine hydrochloride is clinically superior to other drugs, such as tramadol and pantoxan, plus its side effects are better tolerated. Flupirtine hydrochloride has a significant effect on inhibiting neural hyperexcitability and therefore exhibits inhibitory potential in various pain states .
    Flupirtine hydrochloride
  • HY-157956
    LASSBio-873

    		mAChR Neurological Disease
    LASSBio-873 is an orally active muscarinic cholinergic receptor (mAChR) agonist that crosses the blood-brain barrier. LASSBio-873 has potent analgesic effects on acute and inflammatory pain. The analgesic effect of LASSBio-873 can be inhibited by intrathecal injection of the M2 receptor antagonist methoctramine .
    LASSBio-873
  • HY-120456
    SR16835

    		Opioid Receptor Neurological Disease
    SR16835 has high affinity for both NOPr and MOPr, with full agonist activity for NOPr and partial agonist activity for MOPr. SR16835 has no analgesic effect .
    SR16835
  • HY-136644
    PD-217014-methyl ester

    		Others Others
    PD-217014-methyl ester is an α?δ ligand with visceral analgesic activity and can inhibit visceral hypersensitivity, and its anti-hyperalgesic effect is dose-dependent.
    PD-217014-methyl ester
  • HY-136644A
    PD-217014

    		Others Others
    PD-217014 is an α2δ ligand with visceral analgesic activity and can inhibit visceral hypersensitivity reactions. Its anti-allodynic effect is dose-dependent.
    PD-217014
  • HY-P0210
    DAMGO
    4 Publications Verification

    		 Opioid Receptor Cancer
    DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO
  • HY-P0210B
    DAMGO TFA
    4 Publications Verification

    		 Opioid Receptor Cancer
    DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO TFA
  • HY-N4219
    Saikosaponin B3

    		Others Neurological Disease Metabolic Disease
    Saikosaponin B3 is a saikosaponin isolated from the roots of Bupleurum falcatum L., with analgesic effect. Saikosaponin B3 inhibits ACTH-induced lipolysis in the fat cells .
    Saikosaponin B3
  • HY-130118
    MRGPRX1 agonist 1

    		Mas-related G-protein-coupled Receptor (MRGPR) Neurological Disease
    MRGPRX1 agonist 1 is a highly potent agonist of MRGPRX1 (Mas-related G-protein-coupled receptor X1), with an EC50 of 50 nM, and is inactive on MRGPRC11. Analgesic effect .
    MRGPRX1 agonist 1
  • HY-114806
    Fenclofenac

    Flenac; R 67408

    		 Others Inflammation/Immunology
    Fenclofenac is an orally active anti-inflammatory agent with a low ulcerogenic effect. Fenclofenac also exhibits antipyretic and analgesic activities, with an oral LD50 of 2280 mg/kg in rats. Fenclofenac can be utilized in inflammation research .
    Fenclofenac
  • HY-N1965
    Gaultherin

    		Others Inflammation/Immunology
    Gaultherin, a natural salicylate derivative, is isolated from Gaultheria yunnanensis. Gaultherin is a non-steroidal anti-inflammatory drug (NSAID). Gaultherin has analgesic and anti-inflammatory effects and lack gastric ulcerogenic effect compared to Aspirin .
    Gaultherin
  • HY-14316
    Tebanicline

    Ebanicline; ABT-594

    		 nAChR Neurological Disease
    Tebanicline, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.
    Tebanicline
  • HY-14316C
    Tebanicline tosylate

    Ebanicline tosylate; ABT-594 tosylate

    		 nAChR Neurological Disease
    Tebanicline tosylate, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline tosylate exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.
    Tebanicline tosylate
  • HY-103567
    Desmethyl-YM-298198 hydrochloride

    		mGluR Neurological Disease
    Desmethyl-YM-298198 hydrochloride is a high-affinity, selective, and noncompetitive mGluR1 antagonist (IC50: 16 nM). Desmethyl-YM-298198 hydrochloride has analgesic effect in Streptozotocin (HY-13753)-induced hyperalgesic mice .
    Desmethyl-YM-298198 hydrochloride
  • HY-103567A
    Desmethyl-YM-298198

    		mGluR Neurological Disease
    Desmethyl-YM-298198 is a high-affinity, selective, and noncompetitive mGluR1 antagonist (IC50: 16 nM). Desmethyl-YM-298198 has analgesic effect in Streptozotocin (HY-13753)-induced hyperalgesic mice .
    Desmethyl-YM-298198
  • HY-153471
    MOR agonist-1

    		Opioid Receptor Infection Inflammation/Immunology
    MOR agonist-1 is a MOR (μ-opioid receptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders .
    MOR agonist-1
  • HY-P1078
    Huwentoxin XVI

    		Calcium Channel Neurological Disease
    Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI
  • HY-109054
    O-Demethyltramadol

    		Drug Metabolite Neurological Disease
    O-Demethyltramadol is a primary active metabolite of Tramadol. O-Demethyltramadol is mainly responsible for its µ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme .
    O-Demethyltramadol
  • HY-109054A
    O-Desmethyltramadol hydrochloride

    		Drug Metabolite Neurological Disease
    O-Desmethyltramadol (hydrochloride) is a primary active metabolite of Tramadol. O-Demethyltramadol is mainly responsible for its µ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme .
    O-Desmethyltramadol hydrochloride
  • HY-P1329
    CTOP

    		Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-103506
    NNC-711

    NO-711 hydrochloride

    		 GABA Receptor Neurological Disease
    NNC-711 is a potent and selective inhibitor of GAT-1 ( GABA transporter 1) with an IC50 of 40 nM for hGAT-1. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity .
    NNC-711
  • HY-W176629
    Hydrocotarnine

    		E1/E2/E3 Enzyme Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research .
    Hydrocotarnine
  • HY-159562
    COX-2-IN-46

    		COX Inflammation/Immunology
    COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC50=87.74 nM) .
    COX-2-IN-46
  • HY-159561
    COX-1-IN-2

    		COX Inflammation/Immunology
    COX-1-IN-2 (compound 5h) is an anti-inflammatory agent with potent analgesic activity. COX-1-IN-2 exhibits a significant inhibitory effect on COX-1 (IC50=38.76 nM) .
    COX-1-IN-2
  • HY-B0363
    Nimesulide
    5+ Cited Publications

    R805

    		 COX Inflammation/Immunology Cancer
    Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
    Nimesulide
  • HY-P1078A
    Huwentoxin XVI TFA

    		Calcium Channel Neurological Disease
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI TFA
  • HY-N0398R
    Sec-O-Glucosylhamaudol (Standard)

    		Opioid Receptor Neurological Disease
    Sec-O-Glucosylhamaudol (Standard) is the analytical standard of Sec-O-Glucosylhamaudol. This product is intended for research and analytical applications. Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .
    Sec-O-Glucosylhamaudol (Standard)
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-N7694
    Isotoosendanin

    		Others Inflammation/Immunology
    Isotoosendanin is a limonoid that can be isolated from Melia toosendan fruit. Isotoosendanin displays significant anti-inflammatory and analgesic activities .
    Isotoosendanin
  • HY-119820
    Xaliproden free base

    SR57746A free base

    		 5-HT Receptor Neurological Disease
    Xaliproden free base is an orally active and selective 5-HT1A receptor agonist. Xaliproden free base shows analgesic effect against acute tonic nociceptive pain and has neuroprotective effects. Xaliproden free base has an acute inhibitory effect on paclitaxel (HY-B0015)-induced mechanical allodynia by inhibiting the excessive response of primary afferent neurons .
    Xaliproden free base
  • HY-13222
    BAN ORL 24
    1 Publications Verification

    		 Opioid Receptor Neurological Disease Cancer
    BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with KI value of 0.24 nM in CHO cell. BAN ORL 24 can be used for the research of cancer and analgesic .
    BAN ORL 24
  • HY-147377
    N-Salicyloyltryptamine

    		Calcium Channel ERK Potassium Channel Guanylate Cyclase NF-κB Cardiovascular Disease Neurological Disease Inflammation/Immunology
    N-Salicyloyltryptamine acts on voltage-dependent Na +, Ca 2+, and K + ion channels inhibitor. N-Salicyloyltryptamine inhibits K + currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect - .
    N-Salicyloyltryptamine
  • HY-159094
    Nav1.8-IN-15

    		Sodium Channel Neurological Disease
    Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .
    Nav1.8-IN-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: